scholarly journals Effects of Pioglitazone on Asymmetric Dimethylarginine and Components of the Metabolic Syndrome in Nondiabetic Patients (EPICAMP Study): A Double-Blind, Randomized Clinical Trial

PPAR Research ◽  
2013 ◽  
Vol 2013 ◽  
pp. 1-9 ◽  
Author(s):  
Pedram Shokouh ◽  
Adel Joharimoghadam ◽  
Hamidreza Roohafza ◽  
Masoumeh Sadeghi ◽  
Allahyar Golabchi ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Endothelial Function ◽  
Asymmetric Dimethylarginine ◽  
Controlled Trial ◽  
Intervention Group ◽  
Density Lipoprotein ◽  
Double Blind ◽  
Positive Effects ◽  
The Metabolic Syndrome ◽  
Present Trial

The present trial aimed to investigate the effects of pioglitazone on the serum level of asymmetric dimethylarginine (ADMA), a marker of endothelial function, and some indices of inflammation and glucose and lipid metabolism in nondiabetic metabolic syndrome patients. 104 eligible participants (57% female; age between 20 and 70) were enrolled in a double-blind placebo-controlled trial and were randomized to receive either pioglitazone (uptitrated to 30 mg/day) or matching placebo for 24 weeks. Participants were clinically examined and a blood sample was obtained at baseline and at the end of the trial. Pioglitazone significantly improved C-reactive protein level irrespective of changes in insulin sensitivity. Compared with the placebo group, alanine and aspartate transaminases were decreased and high-density lipoprotein cholesterol was increased after treatment with pioglitazone. A considerably greater weight gain was also recorded in the intervention group. We failed to observe any significant changes in serum ADMA in either group and between groups with and without adjustment for age, sex, and components of the metabolic syndrome. In a nutshell, pioglitazone seems to have positive effects on lipid profile, liver transaminases, and systemic inflammation. However, its previously demonstrated endothelial function-improving properties do not seem to be mediated by ADMA.

scholarly journals A Three-Month Consumption of Eggs Enriched with ω-3, ω-5 and ω-7 Polyunsaturated Fatty Acids Significantly Decreases the Waist Circumference of Subjects at Risk of Developing Metabolic Syndrome: A Double-Blind Randomized Controlled Trial

Nutrients ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 663
Author(s):  
Monique T. Ngo Njembe ◽  
Barbara Pachikian ◽  
Irina Lobysheva ◽  
Nancy Van Overstraeten ◽  
Louis Dejonghe ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
At Risk ◽  
Randomized Controlled Trial ◽  
Waist Circumference ◽  
Controlled Trial ◽  
Density Lipoprotein ◽  
Test Group ◽  
Double Blind ◽  
Randomized Controlled ◽  
The Metabolic Syndrome

Alpha-linolenic acid (ALA), docosahexaenoic acid (DHA), rumenic acid (RmA), and punicic acid (PunA) are claimed to influence several physiological functions including insulin sensitivity, lipid metabolism and inflammatory processes. In this double-blind randomized controlled trial, we investigated the combined effect of ALA, DHA, RmA and PunA on subjects at risk of developing metabolic syndrome. Twenty-four women and men were randomly assigned to two groups. Each day, they consumed two eggs enriched with oleic acid (control group) or enriched with ALA, DHA, RmA, and PunA (test group) for 3 months. The waist circumference decreased significantly (−3.17 cm; p < 0.001) in the test group. There were no major changes in plasma insulin and blood glucose in the two groups. The dietary treatments had no significant effect on endothelial function as measured by peripheral arterial tonometry, although erythrocyte nitrosylated hemoglobin concentrations tended to decrease. The high consumption of eggs induced significant elevations in plasma low-density lipoprotein (LDL)- and high-density lipoprotein (HDL)-cholesterol (p < 0.001), which did not result in any change in the LDL/HDL ratio in both groups. These results indicate that consumption of eggs enriched with ALA, DHA, RmA and PunA resulted in favorable changes in abdominal obesity without affecting other factors of the metabolic syndrome.

Therapeutic Lifestyle Modification Program Reduces Plasma Levels of the Chemokines CRP and MCP-1 in Subjects With Metabolic Syndrome

2011 ◽  
Vol 15 (1) ◽  
pp. 48-55 ◽  
Author(s):  
Eui Geum Oh ◽  
So Youn Bang ◽  
Soo Hyun Kim ◽  
Sa Saeng Hyun ◽  
Sang Hui Chu ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Lifestyle Modification ◽  
Controlled Trial ◽  
Intervention Group ◽  
Density Lipoprotein ◽  
High Sensitivity ◽  
Retinol Binding Protein ◽  
Control Group ◽  
Necrosis Factor Alpha ◽  
Hs Crp

Objective: The purpose of this study was to examine the effects of a 6-month therapeutic lifestyle modification (TLM) program on chemokines related to oxidative stress, inflammation, endothelial dysfunction, and arterial stiffness in subjects with metabolic syndrome (MetS). Methods: The authors performed a randomized controlled trial, assigning 52 women (mean age 62.7 ± 9.0 years) with MetS to a TLM intervention group ( n = 31) or a control group ( n = 21). The authors provided the TLM intervention group with health screening, exercise, low-calorie diet, and health education and counseling for 6 months and instructed the control group to maintain their usual lifestyle behaviors. Outcome variables included levels of myeloperoxidase (MPO), oxidized low-density lipoprotein (LDL), adiponectin, leptin, resistin, high-sensitivity C-reactive protein (hs-CRP), interleukin-1β, interleukin-6, tumor necrosis factor-alpha (TNF-α), CD40L, monocyte chemotactic protein-1 (MCP-1), retinol-binding protein 4 (RBP-4), endothelin-1, and brachial-ankle pulse wave velocity. The authors used generalized estimating equation (GEE) analyses to estimate the effects of the TLM program. Results: After the 6-month TLM program, hs-CRP levels decreased significantly, and MCP-1 levels increased at a significantly slower rate in the TLM group than they did in the control group (all p < .05). Conclusion: These results indicate that a TLM program could be effective for improving patient inflammatory states and may also be effective in preventing cardiovascular complications in subjects with MetS.

Abstract 3733: Postprandial Free Fatty Acid Metabolism During Fenofibrate Treatment Predicts Postprandial Lipid And Lipoprotein Changes

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Robert S Rosenson
Keyword(s):  
Metabolic Syndrome ◽  
Test Meal ◽  
Low Density Lipoprotein ◽  
Area Under The Curve ◽  
Density Lipoprotein ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
The Metabolic Syndrome ◽  
Ldl Particles ◽  
Postprandial Triglycerides

Objective: To determine the effects of fenofibrate (160 mg/d) on fasting and postprandial non-esterified fatty acids (NEFA) and lipoproteins in subjects with hypertriglyceridemia and the metabolic syndrome. Methods: Fifty-nine subjects with fasting hypertriglyceridemia (≥1.7 mmol/L and <6.9 mmol/L) and two or more of the Adult Treatment Panel III criteria of the metabolic syndrome were randomized to fenofibrate (160 mg/d) or placebo in a double-blind controlled clinical trial. A standardized fat load (50 g/m 2 ) was given after a 12 h fast. Blood specimens were obtained at fasting and 3.5 h and 8 h after the test meal. Results: After the test meal, postprandial (area under the curve) NEFA increased (mean ± SEM) by 11.2 ± 5.1% in the placebo group; in contrast NEFA decreased by 18.6 ± 3.8% in the fenofibrate group ( P =0.0001). No differences in fasting NEFA were observed between groups ( P =0.16). Fenofibrate reduced postprandial triglycerides (−45.4%, P <0.0001) and significantly decreased postprandial large (−40.8%, P <0.0001) and medium (−49.5%, p<0.0001) very low-density lipoprotein (VLDL) particles, as well as small LDL (−40.3%, P <0.0001) and total LDL particles (−19.0%, P <0.005). Reduction in NEFA (AUC) correlated with reductions in postprandial triglycerides (r=0.73, P <0.0001), non-HDL-C (r=0.67, P <0.0001) and with increases in HDL-C (r=0.38, P <0.01). The reduction in NEFA was more strongly correlated with decreased large VLDL (r=0.72, P <0.0001) than medium VLDL (r=0.34, P <0.02) or small VLDL particles (r=0.22, P <0.13). Postprandial reductions in NEFA were also correlated with lowering of small LDL (r=0.53, P <0.0001) and total LDL particles (r=0.60, P <0.0001). Conclusions: Treatment with fenofibrate significantly decreases postprandial NEFA and the reductions in NEFA are highly correlated with reductions in triglycerides, non-HDL-C and an increase in HDL-C. Postprandial NEFA are an important predictor of postprandial lipoprotein changes in subjects with hypertriglyceridemia.

scholarly journals The Effects of Vitamin E and Omega-3 PUFAs on Endothelial Function among Adolescents with Metabolic Syndrome

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Alireza Ahmadi ◽  
Mojgan Gharipour ◽  
Gholamreza Arabzadeh ◽  
Payam Moin ◽  
Mahin Hashemipour ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Vitamin E ◽  
Endothelial Function ◽  
Controlled Trial ◽  
Elisa Test ◽  
Omega 3 ◽  
Double Blind ◽  
Atherosclerosis Progression ◽  
Major Index ◽  
Endothelial Growth Factor

Aim. The present study aims to explore the effects of vitamin E and omega-3 on endothelial function indicators among adolescents with metabolic syndrome.Method. In a randomized, double blind, and placebo-controlled trial, 90 young individuals, aged 10 to 18 years, with metabolic syndrome were randomly assigned to receive either vitamin E tablets (400 IU/day) or omega-3 tablets (2.4 gr/day) or placebo. For assessing endothelial functional state, the serum level of vascular endothelial growth factor (VEGF) was measured by ELISA test.Results. The use of omega-3 supplementation for eight weeks led to significant increase in serum HDL level compared with the group treated with vitamin E or placebo group. In this regard, no significant correlations were found between the change in VEGF and baseline levels of other markers including anthropometric indices and serum lipids. Omega-3 could significantly reduce VEGF with the presence of other baseline variables (Beta=-12.55;P=0.012).Conclusion. The administration of omega-3 can effectively improve endothelial function in adolescents with metabolic syndrome by reducing the level of serum VEGF, as a major index for atherosclerosis progression and endothelial destabilization. Omega-3 can be proposed as a VEGF antagonist for improving endothelial function in metabolic syndrome. The clinical implications of our findings should be assessed in future studies.

scholarly journals Effect of flaxseed oil supplementation on anthropometric and metabolic indices in patients with coronary artery disease: A double-blinded randomized controlled trial

2019 ◽  
Vol 11 (2) ◽  
pp. 152-160 ◽  
Author(s):  
Sevda Saleh-Ghadimi ◽  
Sorayya Kheirouri ◽  
Ali Golmohammadi ◽  
Jalal Moludi ◽  
Hamed Jafari-Vayghan ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Lipid Profile ◽  
Controlled Trial ◽  
Intervention Group ◽  
Density Lipoprotein ◽  
Flaxseed Oil ◽  
Anthropometric Indices ◽  
Double Blind ◽  
Artery Disease

Introduction: It has been established that omega 3 fatty acids have cardio-protective effects through modulation of cardiometabolic risk factors via multiple mechanisms. The aim of this study was to investigate the effects of flaxseed oil on anthropometric indices and lipid profile in patients with coronary artery disease (CAD). Methods: A randomized, double-blind, placebo-controlled trial was performed in 44 patients with CAD. The subjects were randomly assigned to receive either 200 ml of 1.5% fat milk supplemented by 5 g of flaxseed oil (containing 2.5 g α-Linolenic acid) as intervention or 200 ml of 1.5% fat milk as placebo group for 10 consecutive weeks. Anthropometric indices and lipid profile were assessed at baseline and post-intervention. Results: The results indicated that supplementation with flaxseed oil had no impact on anthropometric indices. Weight, body mass index, waist circumference and hip circumference decreased statistically significant within groups, but not between groups. At the end of the intervention, diastolic blood pressure (DBP) decreased significantly (P = 0.022) in the intervention group. Moreover, the triglyceride (TG) level decreased significantly in the intervention group from 173.45 (49.09) to 139.33 (34.26) (P < 0.001). Other lipid profile indices including total cholesterol, low density lipoprotein and high density lipoprotein did not differ significantly within and between groups. Conclusion: We observed that supplementation of flaxseed oil improved TG and DBP but had no effect on other lipid profiles and anthropometric indices in patients with CAD.

scholarly journals Randomized Clinical Trial: Efficacy of a New Synbiotic in Adults with Metabolic Syndrome

2014 ◽  
Vol 2 ◽  
Author(s):  
Almagul Kushugulova ◽  
Valerii Benberin ◽  
Raushan Karabayeva ◽  
Saule Saduakhasova ◽  
Samat Kozhakhmetov ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Gut Microbiota ◽  
Controlled Trial ◽  
Adult Population ◽  
Glycosylated Hemoglobin ◽  
Density Lipoprotein ◽  
Laboratory Evaluation ◽  
Composition Analysis ◽  
Microbial Composition ◽  
Double Blind

Introduction: Metabolic syndrome is a lifestyle disease and is a frequent problem among the adult population. Human gut microbiota plays a key role in the development of metabolic syndrome. Recently, the gut microbiota has emerged as an important contributor to the development of obesity and metabolic disorders through its interactions with environmental (e.g. diet) and genetic factors. The aim of this study was to research the effects of synbiotic on the gut microbiota and host metabolism. Methods: We conducted a double-blind, randomized, placebo-controlled trial. Our sample included 180 adults (ages 30-89) with symptoms of metabolic syndrome, who were allocated to either placebo or synbiotic group. The main inclusion criteria were: blood pressure of around 130/90 mmHg; raised fasting plasma glucose (FPG) >100 mg/dL (5.6 mmol/L), previous diagnosis of type 2 diabetes, dyslipidemia triglycerides (TG) of 1.70 mmol/L, a high-density lipoprotein cholesterol (HDL-C) of 0.90 mmol/L in males and 1.0 mmol/L in females, and central obesity with a waist/hip ratio > 0.90 in males or > 0.85 in females or a body mass index > 30 kg/m2. Results: We enrolled 90 adults in the placebo group and 90 in the synbiotic group. The two groups had similar demographic and clinical characteristics. Consent was signed by all patients. All patients underwent clinical and laboratory evaluation, including complete blood tests, glucose test, glycosylated  hemoglobin, total cholesterol and triglycerides, cholesterol, LDL, HDL plasma, immunogram, and coprogram. All patients were interviewed with a questionnaire that included 200 questions related to diet, lifestyle, and health. Synbiotic were used by patients in a dose of 200 grams twice a day. The duration of applying of the synbiotic was 90 days. To study the composition of the intestinal microbiota, stool samples were collected before and after applying the synbiotic. The microbial composition will be determined by analyzing the locus of 16S rDNA.Conclusion: This ongoing study is currently undergoing microbial composition analysis in order to establish the efficacy of the new synbiotic in adults with metabolic syndrome.  

The whey fermentation product malleable protein matrix decreases TAG concentrations in patients with the metabolic syndrome: a randomised placebo-controlled trial

2011 ◽  
Vol 107 (11) ◽  
pp. 1694-1706 ◽  
Author(s):  
Ioanna Gouni-Berthold ◽  
Dominik M. Schulte ◽  
Wilhelm Krone ◽  
Jean-François Lapointe ◽  
Pierre Lemieux ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Controlled Trial ◽  
Plasma Lipid ◽  
Primary Objective ◽  
Protein Matrix ◽  
Low Fat ◽  
Double Blind ◽  
Treatment Difference ◽  
The Metabolic Syndrome ◽  
The Difference

Animal and human studies suggest that a malleable protein matrix (MPM) from whey decreases plasma lipid concentrations and may positively influence other components of the metabolic syndrome such as glucose metabolism and blood pressure (BP). The primary objective of this double-blind, multi-centre trial was to investigate the effects of a low-fat yoghurt supplemented with whey MPM on fasting TAG concentrations in patients with the metabolic syndrome. A total of 197 patients were randomised to receive MPM or a matching placebo yoghurt identical in protein content (15 g/d). Patients were treated during 3 months with two daily servings of 150 g yoghurt each to compare changes from baseline in efficacy variables. MPM treatment resulted in a significantly larger reduction of TAG concentrations in comparison to placebo (relative change − 16 %, P = 0·004). The difference was even more pronounced in subjects with elevated fasting TAG ( ≥ 200 mg/dl) at baseline ( − 18 %, P = 0·005). The relative treatment difference in fasting plasma glucose was − 7·1 mg/dl (P = 0·089). This effect was also more pronounced in subjects with impaired fasting glucose at baseline ( − 11 mg/dl, P = 0·03). In patients with hypertension, the relative treatment difference in systolic BP reached − 5·9 mmHg (P = 0·054). The relative treatment difference in body weight was − 1·7 kg (P = 0·015). The most common adverse events were gastrointestinal in nature. Conclusions from the present study are that consumption of a low-fat yoghurt supplemented with whey MPM twice a day over 3 months significantly reduces fasting TAG concentrations in patients with the metabolic syndrome and improves multiple other cardiovascular risk factors.

scholarly journals The Effect of Omega-3 Fatty Acids Supplementation on the Improvement of Metabolic Syndrome in Patients with Ischemic Heart Disease: A Double-blind, Randomised, Placebo-controlled Trial

2020 ◽  
Author(s):  
Asma Zamanian ◽  
Rasoul Zarrin ◽  
Samira Faraji ◽  
Parvin Ayramloy ◽  
Behzad Rahimi Darabad
Keyword(s):  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Fatty Acids ◽  
Placebo Group ◽  
Controlled Trial ◽  
Density Lipoprotein ◽  
Cardiac Ischemia ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
Double Blind

Introduction: Metabolic syndrome is a set of metabolic abnormalities that increase the risk of cardiovascular disease. Omega-3 fatty acids may play a role in improving metabolic syndrome by affecting endothelial status. Aim: To study the effect of omega-3 fatty acids on metabolic syndrome in patients with cardiac ischemia. Materials and Methods: This was a 12-weeks, double-blind, randomised, placebo-controlled trial. Ninety patients with a history of cardiac ischemia and metabolic syndrome were randomly divided into intervention (n=45) and placebo (n=45) groups. In the end, 86 people completed the study. The intervention group consumed daily Omega-3 capsules containing 1000 mg fish oil, 180 mg EPA and 120 mg DHA. The placebo group took gelatin-containing capsules. Serum triglycerides, Fasting Blood Sugar (FBS), cholesterol, Low-Density Lipoprotein (LDL), High-Density Lipoprotein (HDL) were measured at baseline and the end of the study and weight, waist circumference, Body Mass Index (BMI) were measured at baseline, middle and end of the study. Independent t-test was used for comparing the baseline and mean changes. The variables that measured in three times were compared using repeated measurement test between two groups. Paired t-test was performed to compare within group differences. Results: Serum triglyceride, FBS, weight and systolic blood pressure decreased and serum HDL increased compared to the placebo group. There were no significant changes in serum cholesterol, LDL, BMI, waist circumference and diastolic blood pressure after omega-3 administration. Conclusion: Omega-3 supplementation for 12 weeks improves some of the indicators of metabolic syndrome in individuals with ischemic heart disease. (IRCT Code: IRCT20190819044563N1).

Sign in / Sign up

Export Citation Format

Share Document